01 Decentralized and Digital-enabled Veterinary Clinical Trial Models Veterinary clinical trials are increasingly shifting from site-centric studies to decentralized models supported by digital technologies. Remote monitoring tools, wearable animal health devices, telemedicine consultations, and electronic data capture platforms are improving trial efficiency while reducing the need for frequent veterinary hospital visits. This transition enhances owner participation, enables continuous health monitoring, and accelerates data collection for clinical research.
02 Growing Use of Precision Medicine in Veterinary Clinical Research Veterinary clinical research is increasingly focusing on precision medicine by developing therapies tailored to specific genetic profiles, disease biomarkers, and animal breeds. Advances in genomic sequencing and molecular diagnostics are enabling researchers to identify targeted treatment approaches for conditions such as cancer, inherited disorders, and chronic diseases in companion animals. This shift is improving treatment efficacy while supporting the development of innovative therapeutics.
01 The veterinary clinical trials market forecasts continued investment activity driven by rising demand for innovative animal therapeutics and increasing collaboration between pharmaceutical companies, CROs, and academic veterinary institutions.In January 2026, the Weill Family Foundation committed USD 120 million to the UC Davis School of Veterinary Medicine, marking the largest philanthropic donation ever made to a veterinary school. The funding will support the expansion of veterinary clinical research infrastructure, construction of a new small animal teaching hospital, and advancement of translational research capabilities.
01 Rising Animal Drug & Biologics Development and Growing Pet Ownership Drives Market The increasing development of veterinary pharmaceuticals, vaccines, monoclonal antibodies, and biologics is driving demand for veterinary clinical trials. Animal health companies are expanding their research pipelines to address infectious diseases, chronic disorders, and emerging zoonotic threats across companion and livestock animals. This increases the need for well-designed clinical studies to demonstrate product safety and efficacy before regulatory approval.The rising global population of companion animals and increasing expenditure on veterinary healthcare are driving demand for advanced treatment options, supporting growth in veterinary clinical trials. Pet owners are seeking innovative therapies for conditions such as cancer, osteoarthritis, dermatological disorders, and chronic diseases, encouraging manufacturers to invest in new product development. This growing demand expands the number of clinical studies conducted across veterinary hospitals and specialty research centers.
01 Limited Availability of Eligible Trial Participants and High Cost & Operational Complexity of Veterinary Clinical Trials Restrain Market Expansion Veterinary clinical trials often face challenges in enrolling sufficient numbers of eligible animals due to strict inclusion criteria, owner consent requirements, and variations in disease prevalence. In addition, the limited number of specialized veterinary research hospitals and experienced investigators restricts trial capacity in many regions. This slows patient recruitment, delays study completion, and reduces the pace of veterinary product development and market adoption.Veterinary clinical trials require significant investment in study design, patient recruitment, diagnostics, monitoring, regulatory compliance, and data management, making them costly for sponsors. Recruiting eligible animal participants and maintaining protocol compliance across multiple veterinary sites further increases operational complexity.
01 Increasing Development of Livestock Vaccines and Expansion of Regulatory Pathways for Novel Veterinary Therapeutics Offer Growth Opportunities to Market Players The increasing focus on controlling transboundary animal diseases such as African Swine Fever (ASF), Foot-and-Mouth Disease (FMD), and Avian Influenza is creating significant opportunities for veterinary pharmaceutical companies and CROs. Governments and animal health organizations are investing in the development and clinical evaluation of next-generation vaccines and biologics to strengthen food security and disease surveillance.Regulatory agencies are introducing streamlined pathways for innovative veterinary medicines, creating opportunities for sponsors, CROs, and research institutions to accelerate product development. Increasing approvals for monoclonal antibodies, gene-based therapies, regenerative medicine, and advanced biologics require specialized clinical trials to establish safety and efficacy. Companies including Elanco Animal Health and Zoetis are investing in novel therapeutic platforms, which are expected to expand the volume and complexity of veterinary clinical research over the coming years.
01 Limited Availability of Validated Clinical Endpoints and Managing Long-term Follow-up and Owner Compliance Challenges Market Growth The absence of standardized clinical endpoints and validated biomarkers for many animal diseases makes it difficult to consistently measure treatment efficacy across veterinary clinical trials. This can result in variable study outcomes, longer validation timelines, and uncertainty during regulatory review. The development of disease-modifying therapies for canine osteoarthritis has been hindered by the lack of universally accepted objective biomarkers.Many veterinary clinical trials require extended follow-up to evaluate treatment durability and long-term safety, particularly for chronic diseases and biologics. Maintaining pet owner engagement throughout the study period remains difficult, leading to missed assessments and incomplete datasets.